Form
SCHEDULE 13G/A
Passive or exempt beneficial ownership filing.
Invus Global Management, LLC - 31 Mar 2026 SCHEDULE 13G/A Report for Tenax Therapeutics, Inc. Common Stock, $0.0001 par value per share (TENX)
- Filing manager
- Invus Global Management, LLC
- Reporting owner
- Raymond Debbane
- Beneficially owned shares
- 427,141 shares
- Large-stake signal
-
Ownership
2.5%Beneficial ownership of this reported class.
Shares
427,141 sharesShares beneficially owned as disclosed.
Event date
31 Mar 2026Date tied to the ownership event or amendment.
Accepted by SEC
04 May 2026EDGAR acceptance date.
How to read this large-stake filing
- Schedule 13D/G filings focus on beneficial ownership stakes, not a full portfolio.
- Compare this filing with the holder history and issuer page before treating the percentage as a current position.
- Use amendments to understand whether the disclosed stake increased, decreased, or changed reporting status.
- Class ownership
- 2.5%
- Symbol
- TENX
- Shares outstanding
- 17,085,640 shares
- Form type
- SCHEDULE 13G/A
- Accepted by SEC
- 04 May 2026, 14:46:41 UTC
- Event date
- 31 Mar 2026
- Previous filing
- 02 Oct 2025
- SEC filing
- View source filing
Ownership signal
CIK-linked ownership evidence from parsed SEC filings.
2 signals
Subject security
Who this page is about.
2 source fields
Source evidence
Original filing metadata and source links for verification.
5 source fields
Key filing fact
Invus Global Management, LLC disclosed 2.5% ownership in Tenax Therapeutics, Inc. Common Stock, $0.0001 par value per share (TENX) on 31 Mar 2026.
Key facts
- Invus Global Management, LLC filed SCHEDULE 13G/A for Tenax Therapeutics, Inc. Common Stock, $0.0001 par value per share (TENX).
- Disclosed ownership: 2.5%.
- Date of event: 31 Mar 2026.
Change
- Previous schedule filing date: 02 Oct 2025.
- Current filing was accepted on 04 May 2026, 14:46.
Research use
- This page turns one Schedule 13D/G filing into a quick large-stake read before the raw reporting-person rows.
- Use the linked SEC filing as the source of truth for ownership percentages, shares, and reporting-party details.
Evidence
Backed by Schedule 13D/13G
View source filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting persons
Disclosed reporting parties (8)
Names, ownership percentages, voting power, signatures, titles, and CIKs as disclosed in this Schedule 13D/G filing.
| Name | Ownership | Shares owned | Sole voting power | Shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Invus Public Equities, L.P. | 2.1% | 366,143 | 366,143 | 0 | /s/ Raymond Debbane | Raymond Debbane, President of Invus Public Equities Advisors, LLC, its general partner | |
| Invus Public Equities Advisors, LLC | 2.1% | 366,143 | 366,143 | 0 | /s/ Raymond Debbane | Raymond Debbane, President | |
| Invus Global Management, LLC | 2.1% | 366,143 | 366,143 | 0 | /s/ Raymond Debbane | Raymond Debbane, President | |
| Siren, L.L.C. | 2.1% | 366,143 | 366,143 | 0 | /s/ Raymond Debbane | Raymond Debbane, President | |
| Avicenna Life Sci Master Fund LP | 0.4% | 60,998 | 60,998 | 0 | /s/ Raymond Debbane | Raymond Debbane, Chief Executive Officer of Avicenna Life Sci Master GP LLC, its general partner | |
| Avicenna Life Sci Master GP LLC | 0.4% | 60,998 | 60,998 | 0 | /s/ Raymond Debbane | Raymond Debbane, Chief Executive Officer | |
| Ulys, L.L.C. | 0.4% | 60,998 | 60,998 | 0 | /s/ Raymond Debbane | Raymond Debbane, President | |
| Raymond Debbane | 2.5% | 427,141 | 427,141 | 0 | /s/ Raymond Debbane | Raymond Debbane |
CIK / CUSIP context first